At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Berlex Biosciences
- Class Antivirals; Nucleosides; Small molecules
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B; Herpesvirus infections